Fundraising Fox
/Companies
Sign in

Verseau Therapeutics

Auburndale, US · Founded 2017 · Delaware corporation · 6 employees on LinkedIn · 4 known investors

Find your way into Verseau Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

356 people can intro you to Tatiana

Ask Ugur Eskiocak to introduce you to Tatiana Novobrantseva

You →Ugur · together at Voro Therapeutics →Tatiana

205 people can intro you to Igor

Ask Jamie Chen to introduce you to Igor Feldman

You →Jamie · together at Verseau Therapeutics →Igor

44 people can intro you to Christine

Ask Sam Okafor to introduce you to Christine Bunt

You →Sam · together at 20/20 HealthCare Partners →Christine

Sign up to find every way you can get introduced to Verseau Therapeutics

  • Your email: who you already know at Verseau Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Verseau Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Verseau Therapeutics was founded in 2017 by Bob Langer, Dan Anderson, Tatiana Novobrantseva, and Igor Feldman.

BL
Bob LangerCo-founder
DADan Anderson
Dan AndersonCo-founderDan Anderson is an operations professional who has held roles of increasing responsibility and built teams at Verseau Therapeutics, which develops macrophage-targeting monoclonal antibodies for cancer immunotherapy.
TNTatiana Novobrantseva
Tatiana NovobrantsevaTatiana Novobrantseva has worked across drug development modalities including protein and nucleic acid therapeutics, with experience in immunology, inflammation, and immuno-oncology programs. She has held operational and advisory roles at biotech startups focused on bringing novel medicines to patients.
IFIgor Feldman
Igor FeldmanIgor Feldman is a computational biologist who co-founded Verseau Therapeutics and previously led clinical and translational bioinformatics at Moderna, where he supported oncology programs including personalized cancer vaccines using multi-omics data. He has also advised AI-focused biotech companies on translational strategy and computational biology platform development.
WC
Walter CaponeExecutive
CBChristine Bunt
Christine BuntChief Executive Officer, Chairman of the Board, Senior Advisor2017–2021Christine Bunt is Executive Chairman and CEO of Verseau Therapeutics, which she co-founded with professors from MIT; she previously founded and led TARIS Biomedical (acquired by Allergan and J&J) and INTICA Biomedical, and held senior commercial roles at Merck and Roche. She holds degrees in Medical Technology and Immunochemistry from the University of Saarbrücken and has completed executive education at INSEAD and Harvard.

Board

JC
Jong ChangBoard director

Investors · 4

Highlight CapitalreportedNanjin · $2.8M – $74M

How we know: funding news · dealstreetasia.com · Not right? Tell us

Yonghua CapitalreportedShanghai · $142K – $100M

How we know: dealstreetasia.com · Not right? Tell us

Also in the syndicate · 1

3SBio

Reported raises · per SEC filings

Form D private placements

$4.3M disclosed across 1 of 2 rounds · 2017–2019

▶$4.3MraisedMar 2017 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel AndersonExecutive Officer, Director, Promoter
  • Walter CaponeExecutive Officer
  • Robert LangerDirector, Promoter
  • Jong ChangDirector
  • Christine BuntExecutive Officer, Director
Offering amount
$11.4M
Amount sold
$4.3M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Vivace TherapeuticsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Edgewise TherapeuticsEdgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies working in the same space as Verseau Therapeutics.

In the news

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody - BioSpacebiospace.com · Jan 2022

Frequently asked questions

What does Verseau Therapeutics do?
Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients. The company uses a patient-based discovery engine to identify novel targets for immunotherapy, focusing on treating solid tumors where macrophages are prevalent.
Who founded Verseau Therapeutics?
Verseau Therapeutics was founded by Bob Langer, Dan Anderson, Tatiana Novobrantseva, Igor Feldman in 2017.
Who are Verseau Therapeutics's investors?
Verseau Therapeutics's investors include 20/20 HealthCare Partners LLC, Highlight Capital, Yonghua Capital.
How much funding has Verseau Therapeutics raised?
Verseau Therapeutics has disclosed $4.3M raised across 1 of its 2 known rounds.
Where is Verseau Therapeutics headquartered?
Verseau Therapeutics is headquartered in Auburndale, US.